Effects of Simvastatin on Uterine Leiomyoma Size
Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexFemale
Age18-55
SponsorJohns Hopkins University
About this trial
The study aims to study the effect of simvastatin on the size of uterine fibroids.
Eligibility criteria
Qualifiers
Signed informed written consent.
Gender: female.
Age: 18-55 years at time of signing consent.
BMI of subjects: < 45 kg/m2.
Disqualifiers
Pregnancy or lactation.
Previous or current uterine, cervical or ovarian cancer.
Current endometrial hyperplasia or history of atypical endometrial hyperplasia. Endometrial biopsy will be done during screening (if not done within last 12 months).
Suspicion of leiomyosarcoma.
Trial design
Treatments tested in this trial
- Simvastatin 40mg
- Placebo 40 mg
Treatment groups
60 Participants
are divided into 2 treatment groupsSponsors and collaborators
Johns Hopkins University
Lead sponsor
National Institutes of Health (NIH)
Collaborator
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Collaborator
Source ClinicalTrials.gov